Haploidentical stem cell transplantation for lymphoma: a position statement


  • Dawn O'Shea
  • Univadis Medical News
El acceso al contenido completo es sólo para profesionales sanitarios registrados. El acceso al contenido completo es sólo para profesionales sanitarios registrados.

The Lymphoma Working Party of the European Society for Blood and Marrow Transplantation has issued a position statement in relation to the use of haploidentical stem cell transplantation (haploSCT) for patients with lymphoma. 

The document summarises available evidence supporting the use of haploSCT in lymphoma and provides recommendations on how to integrate the treatment in this population.

The position statement says that, based on current data, haploSCT is a valid and safe option for patients with Hodgkin lymphoma (HL) and non-Hodgkin lymphoma (NHL) lacking an HLA 10/10 matched donor.

The group said there is no evidence to favour haploSCT over a matched identical sibling donor (MSD) or 10/10 matched unrelated donors (MUD). The only circumstance in which it might be appropriate to use haploSCT rather than starting a MUD search is if there is an urgency to find a donor or in cases of ethnic minorities, it states.

HaploSCT with either bone marrow (BM) or peripheral blood (PB) as the stem cell sources can be safely performed. It says haploSCT followed by post-transplant cyclophosphamide (PT-Cy) is safe and effective, but there is insufficient data to support reduced intensity or myeloablative conditioning.

The document is published in the journal Bone Marrow Transplant.